ClinicalTrials.gg
Sign In

Drug

Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 clinical trials

Also written QLS31905.

studies test it
5
open now
4
in phase 3
2
first study started
2021

Keep track of what changes. Save the Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.

Watch these studies

How studies write it

Studies that test it under each name

Development codes

QLS31905
4

Studies by the year they started

5 studies that test it; most in 2025 (2)

Studies that test Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905, by start year
YearStudies
20211
20241
20252
20261

By phase

A phase 1/2 study counts in both.

Phase 1
1
Phase 2
2
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it.

Neoplasms
2
Adenocarcinoma
1
Pancreatic Neoplasms
1

Who runs them

Industry 5 · Other 0

Qilu Pharmaceutical Co., Ltd. (5)

Often tested with

Tested in the same studies.

QL2107 (1) · Pembrolizumab (1) · Oxaliplatin (1) · Capecitabine (1) · Gemcitabine (1) · Cisplatin (1) · Iparomlimab/Tuvonralimab (1) · Antineoplastic Agents (1)

Studies

Open first, then newest update. How each study uses Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 is read from its arms, and is right about nine times in ten.

Testing it · 5

Given in every arm · 2 — Anti-Claudin18.2/Anti-CD3 Bispecific Antibody QLS31905 is usual care beside what is tested